Avience Biomedicals IPO
IPO Listing Details
- Listing Date
25 Jun 2026
- Listing Price
₹ 395.20
- Listing Change
90.00%
- Last Traded Price
₹ 338.10
Avience Biomedicals IPO Details
-
Open Date
18 Jun 2026
-
Close Date
22 Jun 2026
- IPO Price Range
₹ 196 to ₹208
- IPO Size
₹ 30.24 Cr
Avience Biomedicals IPO Timeline
Avience Biomedicals IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 18-June-2026 | 0.00 | 13.49 | 15.69 | 10.75 |
| 19-June-2026 | 0.03 | 66.36 | 58.97 | 43.79 |
| 22-June-2026 | 196.77 | 597.23 | 401.22 | 385.25 |
Last Updated: 22 June 2026 5:59 PM by 5paisa
Avience Biomedicals Limited is engaged in manufacturing in-vitro diagnostic (IVD) products and medical devices. The company produces diagnostic kits and medical consumables such as Viral Transport Media, COVID-19 detection kits, HIV kits, HBsAg kits, malaria kits, dengue kits and other diagnostic products.
The company has expanded its product range from IVD rapid test kits to medical devices such as serology products, biochemistry analysers and biochemistry reagents. Its products cater to pathology labs, microbiology labs, hospitals and research centres in India and overseas.
The company also acts as a distributor and trader of medical equipment. Its manufacturing facility is located at G-1, Sector-11, Noida, Gautam Buddha Nagar, Uttar Pradesh. The company has also been allotted land at Plot No. 70, Sector 28, Medical Device Park, YEIDA, Gautam Buddha Nagar, Uttar Pradesh, for setting up a new manufacturing unit.
Incorporated in: December 23, 2019
Managing Director: Mr. Dharam Deo Choudhary
Peers:
No listed peers.
Avience Biomedicals Objectives
1. To part-finance capital expenditure towards setting up a new manufacturing unit at Industrial Plot No. 70, Sector 28, Medical Device Park under YEIDA, Gautam Buddha Nagar, Uttar Pradesh: ₹15.96 crore
2. Funding the working capital requirements of the company: ₹8.25 crore
3. Funds will support general corporate purposes
Avience Biomedicals IPO Size
| Types | Size |
|---|---|
| Total IPO Size |
₹30.24 Cr |
| Offer For Sale | - |
| Fresh Issue |
₹30.24 Cr |
Avience Biomedicals IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 1,200 | 2,35,200 |
| Retail (Max) | 2 | 1,200 | 2,49,600 |
| S-HNI (Min) | 3 | 1,800 | 3,52,800 |
| S-HNI (Max) | 8 | 4,800 | 9,98,400 |
| B-HNI (Min) | 9 | 5,400 | 10,58,400 |
Avience Biomedicals IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 196.77 | 2,73,600 | 5,38,37,400 | 1,119.82 |
| Non-Institutional Buyers | 597.23 | 2,07,000 | 12,36,25,800 | 2,571.42 |
| BNII | 670.18 | 1,38,000 | 9,24,84,600 | 1,923.68 |
| SNII | 451.32 | 69,000 | 3,11,41,200 | 647.74 |
| Individual Investors (IND category bidding for 2 Lots) | 401.22 | 4,81,200 | 19,30,65,600 | 4,015.76 |
| Total** | 385.25 | 9,61,800 | 37,05,28,800 | 7,707.00 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (In ₹ Crores) | FY24 | FY25 |
| Revenue | 23.96 | 45.24 |
| EBITDA | 4.08 | 11.41 |
| PAT | 2.14 | 7.23 |
| Particulars (In ₹ Crores) | FY24 | FY25 |
| Total Assets | 34.65 | 56.52 |
| Share Capital | 3.28 | 4.03 |
| Total Borrowings | 15.13 | 22.16 |
| Cash Flows (₹ Crores) | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | 0.99 | 3.61 |
| Net Cash Generated From / (used in) Investing Activities | (4.03) | (8.81) |
| Net Cash Generated From / (used in) Financing Activities | 2.97 | 9.25 |
| Net Increase (Decrease) in Cash and Cash Equivalents | (0.08) | 4.05 |
Strengths
1. Manufactures in-vitro diagnostic (IVD) products and medical devices, including rapid test kits, serology products, biochemistry analysers and reagents
2. ISO 9001, ISO 13485, ZED MSME Gold and GMP certified manufacturing organisation
3. Products cater to pathology labs, microbiology labs, hospitals and research centres in India and overseas
4. Revenue from operations grew from ₹23.96 crore in FY24 to ₹45.24 crore in FY25, with PAT rising from ₹2.14 crore to ₹7.23 crore
Weaknesses
1. Total borrowings increased from ₹15.13 crore in FY24 to ₹22.16 crore in FY25
2. A majority of revenue from operations comes from traded goods rather than manufactured goods
3. Business depends on demand from hospitals, diagnostic laboratories and research institutions
4. Operates in a competitive diagnostics and medical devices market
Opportunities
1. New manufacturing unit at the Medical Device Park under YEIDA, Gautam Buddha Nagar, can expand production capacity
2. Working capital funding from the IPO can support a larger scale of operations
3. Diversified product range across rapid test kits, analysers, reagents and medical devices offers multiple growth avenues
4. Growing healthcare and diagnostics demand in India supports the IVD products segment
Threats
1. Operates in a competitive diagnostics and medical devices market with domestic and global players
2. Regulatory changes in medical devices and diagnostics can affect product approvals and operations
3. Delays in setting up the new manufacturing unit can affect expansion plans
4. Dependence on raw materials and imported equipment exposes the business to supply chain disruptions
1. Diversified product portfolio across rapid test kits, analysers, reagents and other diagnostic consumables serving hospitals, laboratories and research centres in India and overseas
2. IPO proceeds will fund a new manufacturing unit, working capital requirements and general corporate purposes
Avience Biomedicals operates in the diagnostics and medical devices industry. The company's products are used by pathology labs, microbiology labs, hospitals and research centres for diagnostic and healthcare applications.
The Indian diagnostics and medical device market is supported by rising healthcare awareness, growing testing requirements, preventive health checks and increasing adoption of diagnostic solutions. In-vitro diagnostic products play an important role in disease detection and healthcare delivery. Avience Biomedicals operates across rapid test kits, molecular diagnostic products, analysers, reagents and medical consumables, placing it within the broader diagnostic products value chain.
- Companies
- Type
- Opening On
-
IC Electricals Company
- SME
- 03rd Jul
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Avience Biomedicals IPO opens on June 18, 2026 and closes on June 22, 2026.
The size of the Avience Biomedicals IPO is ₹30.24 Cr.
The price band of Avience Biomedicals IPO is fixed at ₹196 to ₹208 per share.
To apply for Avience Biomedicals IPO, follow the steps given below:
1. Login to your 5paisa demat account and select the issue in the current IPO section
2. Enter the number of lots and the price at which you wish to apply for the Avience Biomedicals IPO
3. Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange
4. You will receive a mandate notification to block funds in your UPI app.
The minimum application size for Avience Biomedicals IPO is 1,200 shares, and the investment required is ₹2,35,200 based on the lower price band.
The share allotment date of Avience Biomedicals IPO is June 23, 2026.
The Avience Biomedicals IPO will tentatively be listed on June 25, 2026.
Fintellectual Corporate Advisors Private Limited is the book running lead manager for Avience Biomedicals IPO.
Avience Biomedicals IPO plans to utilise the raised capital from the IPO for:
1. Part-financing capital expenditure towards setting up a new manufacturing unit at Industrial Plot No. 70, Sector 28, Medical Device Park under YEIDA, Gautam Buddha Nagar, Uttar Pradesh: ₹15.96 crore
2. Funding working capital requirements: ₹8.25 crore
3. General corporate purposes